Insulins Val you Savings Program: Sanofi insulins included in this program are: ADMELOG ® (insulin lispro injection) 100 Units/mL, TOUJEO ® (insulin glargine injection) 300 Units/mL, LANTUS ® (insulin glargine injection) 100 Units/mL and APIDRA ® (insulin glulisine injection) 100 Units/mL. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered. These patients should be observed for signs and symptoms of heart failure. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.įluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death.
Discontinue Lantus, treat and monitor until symptoms resolve.Ī reduction in the Lantus dose may be required in patients with renal or hepatic impairment.Īs with all insulins, Lantus use can lead to life-threatening hypokalemia. Severe life-threatening, generalized allergy, including anaphylaxis, can occur.
Patients should be instructed to always verify the insulin label before each injection. Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus, and may be life-threatening. Do not administer Lantus via an insulin pump or intravenously because severe hypoglycemia can occur. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia.ĭo not dilute or mix Lantus with any other insulin or solution. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Modify insulin regimen only under medical supervision. Monitor blood glucose in all patients treated with insulin. Insulin pens, needles, or syringes must never be shared between patients.
0 kommentar(er)
